Title |
Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma
|
---|---|
Published in |
BMC Cancer, April 2013
|
DOI | 10.1186/1471-2407-13-205 |
Pubmed ID | |
Authors |
Chiharu Tabata, Eisuke Shibata, Rie Tabata, Shingo Kanemura, Koji Mikami, Yoshitaka Nogi, Eriko Masachika, Tomoyuki Nishizaki, Takashi Nakano |
Abstract |
Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin that shows a limited response to conventional chemotherapy and radiotherapy. Therefore, diagnosing MPM early is very important. Some researchers have previously reported that high-mobility group box 1 (HMGB1) was correlated with pulmonary fibrosis. MPM involves the malignant transformation of mesothelial cells, which originate from mesenchymal cells similar to lung fibroblasts. Here, we investigated serum levels of HMGB1 in patients with MPM and compared them with those of a population that had been exposed to asbestos without developing MPM. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Indonesia | 1 | 2% |
United Kingdom | 1 | 2% |
Unknown | 42 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 18% |
Student > Bachelor | 6 | 14% |
Researcher | 5 | 11% |
Student > Master | 5 | 11% |
Student > Doctoral Student | 4 | 9% |
Other | 8 | 18% |
Unknown | 8 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 27% |
Biochemistry, Genetics and Molecular Biology | 7 | 16% |
Agricultural and Biological Sciences | 6 | 14% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
Environmental Science | 1 | 2% |
Other | 4 | 9% |
Unknown | 10 | 23% |